Independent guides and reviews on peptide skincare, anti-aging treatments, and aesthetic trends.
Eli Lilly’s retatrutide Phase 3 results have brought fresh attention to an investigational treatment targeting three hormone receptors involved in metabolic regulation. In results announced on 23 July 2026, Lilly reported average weight reductions of up to 22.6% across two additional late-stage trials. The studies, TRIUMPH-2 and TRIUMPH-3, evaluated different…
If you are searching for tirzepatide pills, the key distinction is between a medicine that contains tirzepatide and a different medicine that happens to come as a tablet. Tirzepatide is approved only as a subcutaneous injection, not as a pill. Its approved injectable brands are Mounjaro and Zepbound. Oral medicines…
Orforglipron has moved from an investigational oral weight-loss drug to an approved prescription option. Marketed by Eli Lilly as Foundayo, it received FDA approval in April 2026 for weight management alongside diet and physical activity in people with obesity, or overweight with a weight-related medical condition. But the approval is…
The brand name for orforglipron is Foundayo. It is a once-daily oral GLP-1 receptor agonist from Eli Lilly and Company, approved by the US Food and Drug Administration on April 1, 2026, for obesity, or overweight with a weight-related condition. One distinction is especially important: orforglipron is not a peptide.…
If you are searching for where to buy retatrutide for weight loss, the most important fact is that there is currently no lawful retail source for human use in the United States. Retatrutide remains investigational and is not approved by the U.S. Food and Drug Administration. Websites advertising it do…
A pill instead of an injection sounds like a simple choice. But the orforglipron vs tirzepatide comparison involves more than convenience. These medicines differ in their molecular structure, how they act, their clinical evidence, and the regulatory status documented in the supplied sources. The most important limitation comes first: there…
Orforglipron side effects include gastrointestinal reactions, headache and hair loss, but the Foundayo safety information also includes warnings that deserve separate attention. These cover thyroid C-cell tumours, pancreatitis, dehydration and acute kidney injury, hypoglycaemia, gallbladder disease, diabetic retinopathy and aspiration during anaesthesia. According to the supplied Lilly announcement, the FDA…
If you have searched for glp3 peptide, you have probably encountered a name that sounds scientific but does not accurately describe a recognised hormone or drug class. The term often appears in online discussions about emerging metabolic medicines, particularly retatrutide. However, GLP-3 is not the correct name for retatrutide, and…
Searching for a cagrilintide retatrutide metabolic outcomes study can lead to a misleading impression: that these two investigational compounds have been tested together or directly compared. The supplied research references do not identify such a study. Instead, they describe separate development programmes from rival pharmaceutical companies, with different treatments, trial…
Eloralintide is Lilly’s investigational, once-weekly injectable amylin-analogue peptide, being studied as a potential treatment for obesity and related metabolic conditions. Formerly known as LY3841136, it is a selective amylin receptor agonist—not an approved medicine. Its clinical development has attracted attention because of substantial weight reductions reported in phase 2 research…